Clinical trial

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-11-09

PhasePHASE3

Study timeline

Study start (actual)2023-11-09Date precision: day

Registry last updated2026-07-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Unresectable Pleural Mesotheliomaunresolved

Interventions

VolrustomigDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

CisplatinDRUG · verified · RxNorm: cisplatin

NivolumabDRUG · verified · RxNorm: nivolumab

IpilimumabDRUG · verified · RxNorm: ipilimumab

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

SeoulSouth Korea3 LondonUnited Kingdom3 PortlandOregon, United States2 BerlinGermany2 BeijingChina2 AnkaraTurkey (Türkiye)2 TianjinChina2 PretoriaSouth Africa2 JohannesburgSouth Africa2 HoustonTexas, United States1 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06097728 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.